natgillin/translations-raw huggingface dataset:
Cetuximab is a chimeric monoclonal IgG1 antibody that is specifically directed against the epidermal growth factor receptor (EGFR). 
Cetuksimab je kimerno monoklonsko IgG1 protutijelo koje je specifično usmjereno prema receptoru za epidermalni čimbenik rasta (EGFR).
Cetuximab binds to the epidermal growth factor receptor (EGFR), an antigen on the surface of certain cancer cells. 
Cetuksimab se veže na receptor epidermalnog čimbenika rasta (EGFR), antigen koji se nalazi na površini određenih stanica karcinoma.
Analyses on the RAS wild-type population are required to appropriately evaluate these data 
Za odgovarajuću procjenu ovih podataka potrebna je analiza populacije s „divljim tipom“
Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck 
Erbitux je indiciran za liječenje bolesnika s karcinomom pločastih stanica glave i vrata
Cetuximab as a single agent or in combination with chemotherapy was investigated in 5 randomised controlled clinical studies and several supportive studies. 
Cetuksimab je kao samostalan lijek ili u kombinaciji s kemoterapijom ispitivan u 5 randomiziranih kontroliranih kliničkih ispitivanja i nekoliko suportivnih ispitivanja.
Combination with other anticancer treatments 
Kombinacija s drugim lijekovima za liječenje karcinoma
• acne-like skin alterations 
• promjene na koži nalik aknama
In a randomised controlled clinical study with 424 patients, reporting rates of severe acute radiation dermatitis and mucositis as well as of late radiation-therapy-related events were slightly higher in patients receiving radiation therapy in combination with cetuximab than in those receiving radiation therapy alone. 
U randomiziranom kontroliranom kliničkom ispitivanju s 424 bolesnika opisani stupnjevi teških akutnih radijacijskih dermatitisa i mukozitisa te kasnijih pojava povezanih sa zračenjem bili su nešto viši kod bolesnika liječenih kombinacijom zračenja i cetuksimaba, nego kod onih koji su samo zračeni.
Cetuximab was started one week before radiation therapy and administered at the doses described in section 4.2 until the end of the radiation therapy period. 
Liječenje cetuksimabom započelo je jedan tjedan prije zračenja u dozama opisanim u poglavlju 4.2 i trajalo je do kraja razdoblja zračenja.
Cetuximab plus FOLFOX4 
Cetuksimab i FOLFOX4
Side effects concerning the lungs 
Nuspojave povezane s plućima
Cetuximab pharmacokinetics were studied when cetuximab was administered as monotherapy or in combination with concomitant chemotherapy or radiation therapy in clinical studies. 
Farmakokinetika cetuksimaba proučavana je kad se cetuksimab primjenjivao kao monoterapija ili u kombinaciji s istodobno primijenjenom kemoterapijom ili zračenjem u kliničkim ispitivanjima.
Cetuximab in combination with radiation therapy for locally advanced disease 
Cetuksimab u kombinaciji sa zračenjem za lokalno uznapredovalu bolest
• For administration with infusion pump or gravity drip (undiluted): Calculate the required volume of Erbitux. 
• Primjena s infuzijskom pumpom ili običnom infuzijom (nerazrijeđen): Izračunajte potrebni volumen Erbituxa.
Toxicity studies with co-administration of cetuximab and chemotherapeutic agents have not been performed. 
Ispitivanja toksičnosti zajedničke primjene cetuksimaba i kemoterapeutika nisu provedena.
What Erbitux contains 
Što Erbitux sadrži
Connect the infusion line and prime it with Erbitux before starting the infusion. 
Spojite infuzijsku liniju i ispunite ju Erbituxom prije započinjanja infuzije.
Please read 'Infusion-related side effects' in section 4 for details, as they may have serious consequences for you, including life-threatening conditions. 
Pročitajte „Nuspojave povezane s infuzijom“ u dijelu 4 za pojedinosti jer mogu imati ozbiljne posljedice za Vas uključujući i po život opasna stanja.
Side effects concerning the skin 
Nuspojave povezane s kožom
Tumour samples from approximately 81% of patients were analysed retrospectively for KRAS expression, of which 55% were KRAS wild-type. 
Uzorci tumora od približno 81% bolesnika analizirani su retrospektivno na ekspresiju KRAS-a; 55% je bilo „divlji tip“ KRAS-a.
Study data demonstrate that patients with metastatic colorectal cancer and activating RAS mutations are highly unlikely to benefit from treatment with cetuximab or a combination of cetuximab and chemotherapy and as add-on to FOLFOX4 a significant negative effect on progression-free survival time (PFS) was shown. 
Podaci iz ispitivanja pokazuju da je vrlo malo vjerojatno da će bolesnici s metastatskim kolorektalnim karcinomom i aktivirajućim mutacijama RAS-a imati koristi od liječenja cetuksimabom ili kombinacijom cetuksimaba i kemoterapije, a kao dodatno liječenje protokolu FOLFOX4 cetuksimab je pokazao značajno negativan učinak na vrijeme preživljenja bez napredovanja bolesti (PFS).
Severe infusion-related side effects include: 
Teške nuspojave povezane s infuzijom uključuju:
There are no data on the effect of cetuximab on human fertility. 
Nema podataka o učinku cetuksimaba na plodnost u ljudi.
Similarly, the pharmacokinetics of irinotecan were unchanged when cetuximab was co-administered. 
Slično tome, farmakokinetika irinotekana je bila nepromijenjena nakon istodobne primjene cetuksimaba.
Very common side effects (may affect more than 1 in 10 people) 
Vrlo česte nuspojave (mogu se pojaviti kod više od 1 na 10 osoba)
Cetuximab is a chimeric monoclonal IgG1 antibody produced in a mammalian cell line (Sp2/0) by recombinant DNA technology. 
Cetuksimab je kimerno monoklonsko IgG1 protutijelo proizvedeno u staničnoj liniji sisavaca (Sp2/0) tehnologijom rekombinantne DNK.
Tumour samples from approximately 81% of patients were analysed retrospectively for KRAS expression. 
Uzorci tumora od približno 81% bolesnika analizirani su retrospektivno na ekspresiju gena KRAS.
EGFR activates proteins called RAS. RAS proteins play an important role in the EGFR pathway -a complex signalling cascade which is involved in the development and progression of cancer. 
RAS bjelančevine imaju važnu ulogu u EGFR putu - kompleksnoj signalnoj kaskadi koja je uključena u razvoj i napredovanje karcinoma.
In tumours, activation of RAS by EGFR contributes to EGFR-mediated increased proliferation, survival and the production of pro-angiogenic factors. 
Kod tumora, aktiviranje gena RAS putem EGFR-a pridonosi povećanoj proliferaciji posredovanoj EGFR-om te preživljenju i tvorbi proangiogenih faktora.
Erbitux may cause side effects concerning the eyes. 
Erbitux može uzrokovati nuspojave na očima.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of solution for infusion contains 5 mg cetuximab. 
KVALITATIVNI I KVANTITATIVNI SASTAV Jedan ml otopine za infuziju sadrži 5 mg cetuksimaba.
In these patients, Erbitux is used alone or in combination with other anticancer medicines. 
Kod ovih bolesnika Erbitux se primjenjuje sam ili u kombinaciji s drugim lijekovima za liječenje karcinoma.
In addition, hypokalaemia may develop as a consequence of diarrhoea. 
Dodatno, kao posljedica proljeva može se pojaviti hipokalemija.
In vitro cetuximab inhibits the production of angiogenic factors by tumour cells and blocks endothelial cell migration. 
In vitro cetuksimab inhibira proizvodnju angiogenetskih čimbenika u tumorskoj stanici i blokira migraciju endotelne stanice.
In both in vitro and in vivo assays, cetuximab inhibits the proliferation and induces apoptosis of human tumour cells that express EGFR. 
I u in vitro i in vivo pokusima, cetuksimab inhibira proliferaciju i potiče apoptozu humanih tumorskih stanica koje iskazuju EGFR.
Do not use Erbitux 
Nemojte primjenjivati Erbitux
Treatment in the cetuximab arm consisted of up to 6 cycles of platinum-based chemotherapy in combination with cetuximab followed by cetuximab as maintenance therapy until disease progression. 
Liječenje u skupini s cetuksimabom sastojalo se od do 6 ciklusa kemoterapije na bazi platine u kombinaciji s cetuksimabom nakon čega slijedi cetuksimab kao terapija održavanja do progresije bolesti.
No conclusive data on the neutralising effect of HACAs on cetuximab is available to date. 
Do danas nisu dostupni relevantni podaci o neutralizirajućem učinku HACA na cetuksimab.
• blood clots in the lungs 
• krvni ugrušci u plućima
In vivo cetuximab inhibits expression of angiogenic factors by tumour cells and causes a reduction in tumour neo-vascularisation and metastasis. 
In vivo cetuksimab inhibira ekspresiju čimbenika angiogeneze na tumorskim stanicama i uzrokuje smanjenje tumorske neovaskularizacije i metastaziranja.
MARKETING AUTHORISATION NUMBERS EU/1/04/281/003 
ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/04/281/003
Of these, 362 patients received cetuximab and oxaliplatin plus fluoropyrimidines (117 patients OxMdG and 245 patients XELOX) and 367 patients received oxaliplatin plus fluoropyrimidines alone (127 patients OxMdG and 240 patients XELOX). 
Od njih, 362 bolesnika su primila cetuksimab i oksaliplatin sa fluropirimidinima (117 bolesnika OxMdG i 245 bolesnika XELOX) a 367 bolesnika su primili samo oksaliplatin i fluoropirimidine (127 bolesnika OxMdG i 240 bolesnika XELOX).
• For administration with infusion pump or gravity drip (diluted with sterile sodium chloride 9 mg/mL (0.9%) solution): Take an infusion bag of adequate size of sterile sodium chloride 9 mg/mL (0.9%) solution. 
• Primjena s infuzijskom pumpom ili običnom infuzijom (razrijeđen 0,9%-tnom (9 mg/ml) sterilnom otopinom natrijeva klorida): Uzmite infuzijsku vrećicu 0,9%-tne (9 mg/ml) sterilne otopine natrijeva klorida odgovarajuće veličine.
Cetuximab in combination with chemotherapy 
Cetuksimab u kombinaciji s kemoterapijom
Limited observations in animals are indicative of a placental transfer of cetuximab, and other IgG1 antibodies have been found to cross the placental barrier. 
Ograničena opažanja na životinjama ukazuju na prijenos cetuksimaba kroz posteljicu kao i drugih IgG1 protutijela.
CRS is normally most severe in relation to the first infusion. 
Sindrom oslobađanja citokina je obično najteži kad je povezan s prvom infuzijom.
Chemotherapy must not be administered earlier than 1 hour after the end of the cetuximab infusion. 
Kemoterapija se ne smije primijeniti u vremenu kraćem od jednog sata nakon završetka infuzije cetuksimabom.
Take an appropriate sterile syringe and attach a suitable needle. 
Uzmite odgovarajuću sterilnu štrcaljku i na nju pričvrstite prikladnu iglu.
There is limited experience with single doses higher than 400 mg/m2 body surface area to date or weekly administrations of doses higher than 250 mg/m 2 body surface area. 
Iskustva s pojedinačnim dozama višim od 400 mg/m2 tjelesne površine ili tjedne primjene doza viših od 250 mg/m2 tjelesne površine su ograničena.
Of the KRAS mutant population, 297 patients received cetuximab and oxaliplatin plus fluoropyrimidines (101 patients OxMdG and 196 patients XELOX) and 268 patients received oxaliplatin plus fluoropyrimidines alone (78 patients OxMdG and 190 patients XELOX). 
Od populacije s mutiranim KRAS-om, 297 bolesnika primilo je cetuksimab i oksaliplatin s fluropirimidinima (101 bolesnik OxMdG i 196 bolesnika XELOX) a 268 bolesnika su primali samo oksaliplatin i fluoropirimidine (78 bolesnika OxMdG i 190 bolesnika XELOX).
• inflammation of the lining of the intestine and mouth 
• upala sluznice crijeva i usta
Connect the infusion line and prime it with the diluted Erbitux before starting the infusion. 
Spojite infuzijsku liniju i ispunite ju razrijeđenim Erbituxom prije započinjanja infuzije.
There were significant dose reductions and delays of capecitabine or oxaliplatin administration mainly due to higher frequency of diarrhoea in the cetuximab containing arm. 
Postojala je značajna redukcija doze i odgode u primjeni kapecitabina ili oksaliplatina uglavnom zbog veće učestalosti proljeva u skupini koja je primala cetuksimab.
Erbitux may be administered via a gravity drip, an infusion pump or a syringe pump. 
Erbitux se može primijeniti putem obične infuziije, infuzijske pumpe ili injekcijske pumpe.
• blood clots in the veins of the legs 
• krvni ugrušci u venama nogu
Squamous cell cancer of the head and neck 
Karcinom pločastih stanica glave i vrata
All subsequent weekly doses are 250 mg cetuximab per m2 each. 
Sve sljedeće tjedne doze su 250 mg cetuksimaba po m
KRAS wild-type population 
populacija „divljeg tipa“
Cetuximab in combination with platinum-based chemotherapy in recurrent and/or metastatic disease 
Cetuksimab u kombinaciji s kemoterapijom na bazi platine kod recidivirajuće i/ili metastatske bolesti
Determination of serum electrolyte levels is recommended prior to and periodically during cetuximab treatment. 
Kontrola elektrolita u serumu preporučuje se prije početka liječenja cetuksimabom te periodično, tijekom liječenja.
If you receive Erbitux with radiation therapy, some of the side effects you may experience can also be related to this combination, such as: 
Ako Erbitux primate u kombinaciji sa zračenjem, neke od nuspojava koje možete osjetiti također se odnose na kombinaciju, kao što su:
Colorectal cancer patients with RAS mutated tumours Cetuximab should not be used in the treatment of colorectal cancer patients whose tumours have RAS mutations or for whom RAS tumour status is unknown. 
Cetuksimab se ne smije koristiti za liječenje bolesnika s kolorektalnim karcinomom čiji tumori imaju RAS mutaciju ili kod kojih je RAS status tumora nepoznat.
In patients with recurrent and/or metastatic squamous cell cancer of the head and neck, cetuximab is used in combination with platinum-based chemotherapy followed by cetuximab as maintenance therapy until disease progression (see section 5.1). 
Kod bolesnika s rekurentnim i/ili metastatskim karcinomom pločastih stanica glave i vrata, cetuksimab se primjenjuje u kombinaciji s kemoterapijom na bazi platine koju slijedi cetuksimab kao terapija održavanja do progresije bolesti (vidjeti dio 5.1).
• breathing difficulties 
• poteškoće pri disanju
When prescribing cetuximab, the cardiovascular and performance status of the patients and concomitant administration of cardiotoxic compounds such as fluoropyrimidines should be taken into account. 
Kod propisivanja cetuksimaba potrebno je uzeti u obzir kardiovaskularni i opći status bolesnika te istovremenu primjenu kardiotoksičnih tvari kao što su fluoropirimidini.
Pre-treatment 
Predliječenje
In the KRAS wild-type population of the CALGB/SWOG 80405 study (n=1137), superiority of cetuximab plus chemotherapy over bevacizumab plus chemotherapy was not shown based on an interim analysis. 
Na temelju interim analize podataka iz ispitivanja 80405 CALGB/SWOG (n=1137) nije dokazana nadmoć cetuksimaba i kemoterapije nad bevacizumabom i kemoterapijom u populaciji s „divljim tipom“
It is recommended to start cetuximab therapy one week before radiation therapy and to continue cetuximab therapy until the end of the radiation therapy period. 
Preporučuje se liječenje cetuksimabom započeti jedan tjedan prije početka zračenja te liječenje cetuksimabom nastaviti do kraja zračenja.
No other formal interaction studies with cetuximab have been performed in humans. 
Druga formalna ispitivanja interakcija cetuksimaba kod ljudi nisu provedena.
The RAS mutant population consists of patients with known KRAS exon 2 mutations as well as additionally identified RAS mutations. 
Populacija s mutiranim RAS-om sastoji se od bolesnika s poznatim mutacijama eksona 2 KRAS-a, kao i s naknadno utvrđenim mutacijama RAS-a.
In these patients, Erbitux is used in combination with radiation therapy or with other anticancer medicines. 
Kod ovih se bolesnika Erbitux koristi u kombinaciji sa zračenjem ili drugim lijekovima za liječenje karcinoma.
In patients with metastatic colorectal cancer, cetuximab is used in combination with chemotherapy or as a single agent (see section 5.1). 
Kod bolesnika s metastatskim kolorektalnim karcinomom, cetuksimab se primjenjuje u kombinaciji s kemoterapijom ili kao samostalan lijek (vidjeti dio 5.1).
Erbitux may cause infusion-related side effects. 
Erbitux može uzrokovati nuspojave povezane s infuzijom.
Draw up the required volume of Erbitux from a vial. 
Izvucite potrebni volumen Erbituxa iz bočice.
• with polyethylene (PE), ethyl vinyl acetate (EVA) or polyvinyl chloride (PVC) bags, 
• vrećicama od polietilena (PE), etilvinilacetata (EVA) ili polivinilklorida (PVC),
Connect the infusion line to the syringe, set and control the rate as explained in section 4.2 and start the infusion after priming the line with Erbitux or sterile sodium chloride 9 mg/mL (0.9%) solution. 
Spojite infuzijsku liniju na štrcaljku, postavite i kontrolirajte brzinu kako je objašnjeno u dijelu 4.2 te započnite infuziju nakon što se linija ispuni Erbituxom ili 0,9%-tnom (9 mg/ml) sterilnom otopinom natrijeva klorida.
• The other ingredients are sodium chloride, glycine, polysorbate 80, citric acid monohydrate, sodium hydroxide and water for injections. 
• Drugi sastojci su: natrijev klorid, glicin, polisorbat 80, citratna kiselina hidrat, natrijev hidroksid i voda za injekcije.
Patients who receive cetuximab in combination with platinum-based chemotherapy are at an increased risk for the occurrence of severe neutropenia, which may lead to subsequent infectious complications such as febrile neutropenia, pneumonia or sepsis. 
Kod bolesnika koji primaju cetuksimab u kombinaciji s kemoterapijom na bazi platine povećan je rizik od pojave teške neutropenije koja može voditi do daljnjih infekcijskih komplikacija kao što su febrilna neutropenija, pneumonija ili sepsa.
Cetuximab also targets cytotoxic immune effector cells towards EGFRexpressing tumour cells (antibody dependent cell-mediated cytotoxicity, ADCC). 
Cetuksimab također usmjerava citotoksične imunološke efektorske stanice prema tumorskim stanicama koje iskazuju EGFR (stanično posredovana citotoksičnost ovisna o protutijelu, ADCC).
• drying out which may be due to diarrhoea or reduced fluid intake 
• dehidracija zbog proljeva ili smanjenog unosa tekućine
Each subsequent dose (250 mg/m² body surface area) is infused in approximately 1 hour with an infusion rate not faster than 10 mg/min. 
Svaka sljedeća doza je 250 mg/m² tjelesne površine u infuziji koja traje otprilike 1 sat pri brzini infuzije ne većoj od 10 mg/min.
They must not be administered earlier than 1 hour after the end of the cetuximab infusion. 
Oni se ne smiju primijeniti u vremenu kraćem od jednog sata nakon kraja infuzije cetuksimaba.
Use a gravity drip or an infusion pump for administration. 
Za primjenu koristite običnu infuziju ili infuzijsku pumpu.
Skin reactions are very common and treatment interruption or discontinuation may be required. 
Kožne reakcije su vrlo česte te mogu iziskivati privremeni ili trajni prekid liječenja.
In all indications, Erbitux is administered once a week. 
Erbitux se kod svih indikacija primjenjuje jednom tjedno.
• The active substance is cetuximab. 
• Djelatna tvar je cetuksimab.
FIRE-3 (First-line combination of cetuximab with FOLFIRI): The FIRE-3 study was a multicentre randomised phase-III study investigating head-to-head 5-FU, folinic acid and irinotecan (FOLFIRI) combined with either cetuximab or bevacizumab in patients with KRAS exon 2 wild-type metastatic colorectal cancer (mCRC). 
FIRE-3 (Kombinacija cetuksimaba s FOLFIRI-jem u prvoj liniji liječenja): Ispitivanje FIRE-3 bilo je multicentrično, randomizirano ispitivanje faze III u kojem je izravno uspoređeno liječenje 5-FU, folnom kiselinom i irinotekanom (FOLFIRI) u kombinaciji ili s cetuksimabom ili s bevacizumabom u bolesnika s metastatskim kolorektalnim karcinomom (mCRC) s „divljim tipom“ eksona 2 KRAS-a.
• EMR 62 202-006: This randomised study compared the combination of cetuximab and radiation therapy (211 patients) with radiation therapy alone (213 patients) in patients with locally advanced squamous cell cancer of the head and neck. 
• EMR 62 202-006: Ovo randomizirano ispitivanje usporedilo je kombinaciju cetuksimaba i zračenja (211 bolesnika) sa zračenjem samim (213 bolesnika) kod bolesnika s lokalno uznapredovalim karcinomom pločastih stanica glave i vrata.
FIRE-3, an investigator-sponsored clinical phase-III study, compared the treatment of FOLFIRI in combination with either cetuximab or bevacizumab in the first-line treatment of patients with KRAS exon 2 wild-type mCRC. 
U FIRE-3, kliničkom ispitivanju faze III koje su sponzorirali ispitivači, uspoređivano je liječenje FOLFIRI-jem u kombinaciji ili s cetuksimabom ili s bevacizumabom u prvoj liniji liječenja bolesnika s mCRC s „divljim tipom“ eksona 2 KRAS-a.
What Erbitux is 
Što je Erbitux
• For administration with a syringe pump: Calculate the required volume of Erbitux. 
• Za primjenu s injekcijskom pumpom: Izračunajte potrebni volumen Erbituxa.
In contrast to progression free survival time, no benefit in overall survival time could be demonstrated in patients with KPS ≤ 80 who were 65 years of age or older. 
Suprotno vremenu preživljenja bez napredovanja bolesti, kod bolesnika s KPS ≤ 80, starosti 65 godina i starijih, nije se mogla dokazati korist u ukupnom vremenu preživljenja.
No non-clinical data on the effect of cetuximab on wound healing are available to date. 
Do danas nema nekliničkih podataka o učinku cetuksimaba na zacjeljivanje rana.
In patients with locally advanced squamous cell cancer of the head and neck, cetuximab is used concomitantly with radiation therapy. 
Kod bolesnika s lokalno uznapredovalim karcinomom pločastih stanica glave i vrata, cetuksimab se primjenjuje u kombinaciji sa zračenjem.
Cetuximab plus OxMdG 
Cetuksimab i OxMdG
The first dose (400 mg/m² body surface area) is infused over a period of approximately 2 hours with an infusion rate not faster than 5 mg/min. 
Prva je doza 400 mg/m² tjelesne površine u infuziji koja traje otprilike 2 sata pri brzini infuzije ne većoj od 5 mg/min.
If a diagnosis of ulcerative keratitis is confirmed, treatment with cetuximab should be interrupted or discontinued. 
U slučaju potvrđene dijagnoze ulceroznog keratitisa liječenje cetuksimabom treba privremeno ili trajno prekinuti.
Confounding or contributing factors, such as concomitant chemotherapy known to be associated with ILD, and pre-existing pulmonary diseases were frequent in fatal cases. 
U slučajevima sa smrtnim ishodom često su bili prisutni zbunjujući faktori ili faktori koji doprinose razvoju bolesti, kao što je istodobno primijenjena kemoterapija za koju je poznato da je povezana s ILD-om, te prethodno postojeće bolesti pluća.
Evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with Erbitux. 
Prije početka liječenja Erbituxom potrebno je potvrditi RAS (KRAS i NRAS) status „divljeg tipa“.
Patients with a good prognosis as indicated by tumour stage, Karnofsky performance status (KPS) and age had a more pronounced benefit, when cetuximab was added to platinum-based chemotherapy. 
Bolesnici s dobrom prognozom, s obzirom na stadij tumora, opći status prema Karnofskom (KPS) te dob, imali su mnogo izraženiju korist kada je kemoterapiji na bazi platine dodan cetuksimab.
In some studies association with age ≥ 65 years or performance status has been observed. 
U nekim je ispitivanjima opažena povezanost s dobi bolesnika ≥ 65 godina te općim statusom.
In combination with fluoropyrimidines, the frequency of cardiac ischaemia including myocardial infarction and congestive heart failure as well as the frequency of hand-foot syndrome (palmar-plantar erythrodysaesthesia) were increased compared to that with fluoropyrimidines. 
U kombinaciji s fluoropirimidinima, u odnosu na samostalnu primjenu fluoropirimidina, povećala se učestalost ishemije srca, uključujući infarkt miokarda, kongestivno zatajivanje srca kao i učestalost sindroma šake i stopala (palmarno-plantarne eritrodisestezije).
Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)expressing, RAS wild-type metastatic colorectal cancer 
Erbitux je indiciran za liječenje bolesnika s metastatskim kolorektalnim karcinomom koji iskazuje receptor za epidermalni čimbenik rasta (EGFR) s „divljim tipom“ gena RAS